BioSpace News Archive

Drug Development

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK.

August 1, 2023
·
6 min read
Deals

HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM

Harmony Biosciences Holdings, Inc. today announced that its Board of Directors authorized the repurchase of up to $125 million of the Company’s common stock.

August 1, 2023
·
5 min read
Business

TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2023, along with recent company developments, and a business outlook for 2023.

August 1, 2023
·
20 min read
Bio NC

RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a wholly owned subsidiary of the Ghassan Aboud Group, has received marketing approval from the United Arab Emirates Ministry of Health for Talicia.

August 1, 2023
·
15 min read
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. announced the execution of an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in the People’s Republic of China.

August 1, 2023
·
7 min read
Business

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

Xeris Biopharma Holdings, Inc. today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, August 8, 2023.

August 1, 2023
·
2 min read
Genetown

Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 3:00 p.m. ET.

August 1, 2023
·
1 min read
Policy

Etiometry Gains FDA Clearance of AI-Based Algorithm that Alerts Risk of Hypercapnia for Neonates in Critical Care

Etiometry, the leader in clinical decision-support software, announced its IVCO2 Index™ was cleared by the Food and Drug Administration for use with neonatal ICU patients under 2kg, who are especially vulnerable to the effects of hypercapnia.

August 1, 2023
·
3 min read
Business

CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023

CytomX Therapeutics, Inc. today announced that it will report second quarter financial results on Tuesday, August 8, 2023, after the close of U.S. markets.

August 1, 2023
·
2 min read
Genetown

APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference

Apnimed, Inc. announced today the company will be participating in the upcoming 43rd Annual Canaccord Genuity Global Growth Conference at the InterContinental in Boston, Massachusetts on Wednesday, August 9, 2023.

August 1, 2023
·
3 min read